🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

119 results for “Cancer Prevention Pharma (Ireland) Limited” Clear

  1. KIMMTRAK 100 micrograms/0.5 mL concentrate for solution for infusion

    Cancer Prevention Pharma (Ireland) Limited

    Uveal Melanoma

    phase 3 small molecule active

    1 trial

  2. LETROZOLE, ANASTROZOLE, CAPECITABINE, PACLITAXEL, CAPECITABINE, Verzenios 50 mg film-coated tablets, FULVESTRANT

    Cancer Prevention Pharma (Ireland) Limited

    Patients with untreated metastatic Estrogen Receptor positive (ER+), Human Epidermal Growth Factor Receptor-2 negative (HER2-) breast cancer with visceral involvement

    phase 3 small molecule active

    1 trial

  3. LETROZOLE, DOCETAXEL, ANASTROZOLE, LEUPRORELIN ACETATE, LEUPRORELIN ACETATE, TAMOXIFEN, EPIRUBICIN, DOXORUBICIN, GOSERELIN, TRIPTORELIN, EXEMESTANE, PACLITAXEL, CYCLOPHOSPHAMIDE, GOSERELIN, TRIPTORELIN

    Cancer Prevention Pharma (Ireland) Limited

    Premenopausal patients with high-risk HR-positive/HER2-negative breast cancer (BC) defined by tumour size and axillary lymph node status. One of the following must apply: a. 1-3 lymph nodes involved AND any invasive tumour size. b. node negative (including micrometastases in at least 1 node [i.e. deposit >0.2-2mm diameter]) AND invasive tumour size ≥ 50mm.

    phase 3 small molecule active

    1 trial

  4. LETROZOLE, EXEMESTANE, ANASTROZOLE, PALBOCICLIB, FULVESTRANT

    Cancer Prevention Pharma (Ireland) Limited

    ER+/HER2- metastatic breast cancer

    phase 3 small molecule active

    1 trial

  5. LEUPRORELIN ACETATE, BAY 1841788, NUBEQA 300 mg film-coated tablets, TRIPTORELIN, DEGARELIX, GOSERELIN

    Cancer Prevention Pharma (Ireland) Limited

    Castrate-resistant prostate cancer with oligometastases on functional imaging (PSMA or choline/fluciclovine-positron-emission tomography).

    phase 3 small molecule active

    1 trial

  6. LOMUSTINE

    Cancer Prevention Pharma (Ireland) Limited

    Glioblastoma

    phase 3 small molecule active

    1 trial

  7. NUBEQA 300 mg film-coated tablets, Placebo to BAY1841788 film-coated tablet 300 mg

    Cancer Prevention Pharma (Ireland) Limited

    Localised Very High-Risk Cancer of the Prostate

    phase 3 small molecule active

    1 trial

  8. OXALIPLATIN, CALCIUM LEVOFOLINATE, FOLINIC ACID, FLUOROURACIL

    Cancer Prevention Pharma (Ireland) Limited

    Patients ≥75 years old with cT3/T4 rectal adenocarcinoma eligible to radiotherapy, FOLFOX chemotherapy and total mesorectal excision (TME) surgery

    phase 3 small molecule active

    1 trial

  9. OXALIPLATIN, FOLINIC ACID, IRINOTECAN, FLUOROURACIL

    Cancer Prevention Pharma (Ireland) Limited

    High-risk stage III colon cancer

    phase 3 small molecule active

    1 trial

  10. PACLITAXEL, FLUOROURACIL, DOCETAXEL, EXEMESTANE, DOXORUBICIN, CYCLOPHOSPHAMIDE, EPIRUBICIN, LETROZOLE, TAMOXIFEN, ANASTROZOLE

    Cancer Prevention Pharma (Ireland) Limited

    patients with node positive breast cancer who do not have high Recurrence Scores (RS) by Oncotype DX®

    phase 3 small molecule active

    1 trial

  11. PACLITAXEL, LEUPRORELIN, GOSERELIN, TRIPTORELIN, EPIRUBICIN, TRIPTORELIN, EXEMESTANE, RIBOCICLIB, CYCLOPHOSPHAMIDE, LETROZOLE, DOXORUBICIN, GOSERELIN, LEUPRORELIN, ANASTROZOLE, PACLITAXEL ALBUMIN-BOUND, DOCETAXEL

    Cancer Prevention Pharma (Ireland) Limited

    Patients with HR+ HER2- early breast cancer at intermediate risk of recurrence and eligible for adjuvant chemotherapy

    phase 3 small molecule active

    1 trial

  12. PEMBROLIZUMAB

    Cancer Prevention Pharma (Ireland) Limited

    Squamous cell carcinoma of head and neck

    phase 3 small molecule active

    1 trial

  13. PEMBROLIZUMAB

    Cancer Prevention Pharma (Ireland) Limited

    Patient with early triple-negative breast cancer (TNBC) achieving pathologic complete response (pCR) after neoadjuvant systemic chemotherapy and pembrolizumab.

    phase 3 small molecule active

    1 trial

  14. PEMETREXED, PEMBROLIZUMAB, CISPLATIN, PACLITAXEL, PACLITAXEL ALBUMIN-BOUND, CARBOPLATIN

    Cancer Prevention Pharma (Ireland) Limited

    Advanced (stage IIIB/IIIC/IV) NSCLC patients eligible for treatment with a PD-1 antagonist (pembrolizumab) according to the European Marketing Authorisation in a first line

    phase 3 small molecule active

    1 trial

  15. Paclitaxel 6mg/ml Concentrate for Solution for Infusion, Doxorubicin Teva 2 mg/ml Concentrate for Solution for Infusion, Fluorouracil 50 mg/ml Solution for Injection or Infusion, Tamoxifen 20 mg Tablets, Epirubicin 2 mg/ml Solution for Injection, Endoxana Injection 500 mg Powder for Solution for Injection, Anastrozole 1 mg film-coated tablets, TAXOTERE 20 mg/0.5 ml concentrate and solvent for solution for infusion

    Cancer Prevention Pharma (Ireland) Limited

    Patients with 1-3 positive Nodes, Hormone Receptor-Positive and Her2-Negative Breast Cancer with recurrence Score (RS) of 25 or Less

    phase 3 small molecule active

    1 trial

  16. Placebo tablets to match S95032 drug product are supplied as film-coated tablets for oral administration., S95032/AG-881, S95032/AG-881

    Cancer Prevention Pharma (Ireland) Limited

    ​​IDH-mutant grade 2 or 3 astrocytoma​

    phase 3 small molecule active

    1 trial

  17. Placebo, CEMIPLIMAB

    Cancer Prevention Pharma (Ireland) Limited

    Non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  18. Tecentriq 1 200 mg concentrate for solution for infusion

    Cancer Prevention Pharma (Ireland) Limited

    High-risk non-muscle invasive bladder cancer (NMIBC) after transurethral resection of the bladder (TURBT) and pathological assessment.

    phase 3 small molecule active

    1 trial

  19. Tecentriq 1 200 mg concentrate for solution for infusion, Avastin 25 mg/ml concentrate for solution for infusion.

    Cancer Prevention Pharma (Ireland) Limited

    Metastatic (stage IVB), Persistent, or Recurrent Carcinoma of the Cervix

    phase 3 small molecule active

    1 trial

  20. Trazimera 420 mg powder for concentrate for solution for infusion, Perjeta 420 mg concentrate for solution for infusion, VINORELBINE ARROW 10 mg/ml, solution à diluer pour perfusion, TherO2-01S22, PACLITAXEL AHCL 6 mg/ml, solution à diluer pour perfusion, Placebo syrup, Docetaxel Accord 160 mg/8 ml concentrate for solution for infusion

    Cancer Prevention Pharma (Ireland) Limited

    metastatic breast cancer

    phase 3 small molecule active

    1 trial

  21. Xofigo 1100 kBq/mL solution for injection

    Cancer Prevention Pharma (Ireland) Limited

    metastatic Castration-Resistant Prostate Cancer (mCRPC)

    phase 3 small molecule active

    1 trial

  22. Xtandi - 40 mg soft capsules, Flutamide 250 mg Tablets, Casodex® 50 mg Film-coated Tablets

    Cancer Prevention Pharma (Ireland) Limited

    Metastatic Prostate Cancer

    phase 3 small molecule active

    1 trial

  23. Xtandi - 40 mg soft capsules, Xofigo 1100 kBq/mL solution for injection

    Cancer Prevention Pharma (Ireland) Limited

    Castration resistant prostate cancer patients metastatic to bone.

    phase 3 small molecule active

    1 trial

  24. Zometa 4 mg/100 ml solution for infusion

    Cancer Prevention Pharma (Ireland) Limited

    High grade osteosarcoma

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources